Abstract 2783
Background
Individual Care plans should be a co-creation between the patient and the health care provider, and should be updated by the contact nurse (CN) that is the patients’ main point of contact. Until recently the individual care plans for patients with Head & Neck cancer (H&N) in our region constituted of extensive written information in a ring binder and in addition a treatment plan from the medical records were printed and given to the patient. This quality improvement project aims to implement a digital and interactive version of the care plan, with a greater possibility to tailor information and increased availability. The implementation process contained of both the introduction of the digital tool (the care plan) and also new work processes for the nurses.
Methods
We followed the Plan Do Study Act approach. A clinical nurse leader together with the designer of the and an IT-technician worked together with the preparations (education, testing and risk assessment). All patients with H&N cancer could choose a standard care plan or the new digital format. The digital care plan was prepared by the CN. A person-centered approach was adopted for the digital care plans, with mandatory questions at the first visit with the CN; “What is important to you? - What is important that I know about you?”.
Results
30 % of chose the digital version of the individual care plan (n = 45) (patients were asked to choose either printed or digital). Patients and nurses were asked to give feedback on the content, usefulness and to suggest improvements. The first evaluation from the patients suggests improved patient participation and satisfaction. The CN stated that the digital care plan had advantages such as less time consuming, improved communication with the patients and supporting person-centered care. The patients can interact with the CN and may also use different symptom assessment scales and were involved during the whole implementation phase.
Conclusions
There is a potential for increased use of screening tools and systematic assessment of symptoms with the digital version of the IWCP. The mandatory question gave important information to the CN to consider. A designated nurse leader involved in the process is important during the implementation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Regional Cancer Center Stockholm Gotland.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract
5218 - Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
Presenter: Bram De Laere
Session: Poster Display session 3
Resources:
Abstract